DRUG DEVELOPMENT DECONSTRUCTOR MANIFESTO: :
“Tell me how you read and I'll tell you who you are.” ― Martin Heidegger
Pages
▼
Tuesday, July 7, 2015
Market based medicine development
Sembragiline, a joint development project for Alzheimer's disease from Roche and Evotec, did not demonstrate cognitive benefit in treated patients with Alzheimer's disease (AD) after 52 weeks.
This is the second AD drug failure for Roche in the last two years, including gantenerumab, which failed late last year.
Evotec is still dedicated to CNS R&D, and has more than 70 CNS-related products at various stages of development in their portfolio, according to Evotec CEO Werner Lanthaler.
No comments:
Post a Comment